2025 Q4 -tulosraportti
63 päivää sitten
‧44 min
Tarjoustasot
Nasdaq Stockholm
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 22 892 | - | - | ||
| 14 553 | - | - | ||
| 22 703 | - | - | ||
| 19 262 | - | - | ||
| 18 484 | - | - |
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 5.5. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 12.2. | ||
2025 Q3 -tulosraportti 23.10.2025 | ||
2025 Q2 -tulosraportti 10.7.2025 | ||
2025 Q1 -tulosraportti 24.4.2025 | ||
2024 Q4 -tulosraportti 22.1.2025 |
Asiakkaat katsoivat myös
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
·4 t sitten
·3 t sitten · MuokattuThen this news is under That an abstract is under embargo means that the content is subject to a publication stop until a specific date and time. This is common in research, medicine, and journalism to ensure a coordinated release of news or results. Science & Public Science & Public +2 Here's what it means in practice: Confidentiality: The information in the abstract is confidential and may not be disseminated, published, or discussed publicly before the specified time. Purpose: Embargoes are often used at scientific conferences or journal publications so that journalists and researchers have time to prepare their reporting without anyone "jumping the gun". Academic works: For dissertations or theses, an embargo may mean that the entire text is locked (for example, due to patent applications or collaboration with companies), even if the title and author name are sometimes still visible. Duration: An embargo period usually lasts between 6 and 12 months, but at conferences, it is often only a matter of days or hours until the actual- ·10 t sittenIt's only a matter of time before we go up over 1kr .. this text is copied Here you get the translation to Danish. I must say that they all possess good competencies :) Comprehensive financial investigation and strategic research report: Alligator Bioscience AB (ATORX) Analysis of company management and management competencies Alligator Bioscience's operational integrity and strategic development are fundamentally dictated by a management team that combines deep scientific background with specialized experience in biotechnological commercialization. The company, headquartered in Medicon Village in Lund, Sweden, has successfully evolved from a discovery-focused antibody shop to a clinical-stage powerhouse, a transition that requires a nuanced management strategy to handle the high capital requirements associated with late-stage studies. The senior management is led by CEO Søren Bregenholt, who assumed the role in June 2021. Bregenholt has a distinguished 20-year career in the global pharmaceutical and biotech sector with previous leading positions at Novo Nordisk, Symphogen, and Macrophage Pharma. His background is particularly relevant to Alligator's current needs, as he has a documented track record of negotiating and operationalizing license and co-development agreements, which is crucial for the company's "Phase 3-ready" leading asset, mitazalimab. CFO Johan Giléus, appointed in 2024, complements the CEO. Giléus is an experienced finance director with over 25 years of experience leading financial operations and strategy across multiple sectors. His most recent role as CFO and VP at InDex Pharmaceuticals, where he oversaw a large clinical Phase 3 study and successfully managed a reverse merger, provides the specific financial engineering expertise Alligator needs to navigate its current capital structure challenges. The scientific vision is anchored by Peter Ellmark, Chief Scientific Officer, who has been an integral part of the company's management since 2018 and previously served as VP for Discovery. Ellmark's deep understanding of the proprietary RUBY™ and Neo-X-Prime™ platforms ensures that the company's research and development results remain scientifically stringent and differentiated in an overcrowded immuno-oncology market. The Board of Directors, with Hans-Peter Ostler as chairman, provides a robust oversight layer with a varied mix of scientific, industrial, and strategic expertise. Board members, such as Eva Sjökvist Saers and Karin Nordbladh, maintain a high degree of independence from major shareholders, which is a hallmark of strong corporate governance for a public entity. This independence is crucial for a micro-based biotechnology company, where strategic decisions, such as dilution rights or partnership terms, must balance the existing shareholder base with the company's long-term survival.
·6 t sittenand I who thought this stock would go to ten kroner in two days;-) 
11 t sitten11 t sittenComprehensive Financial Investigation and Strategic Research Report: Alligator Bioscience AB (ATORX) https://g.co/gemini/share/c495a5c989b8·10 t sittenHere you get the translation into Danish. I must say that they all possess good competencies :) Comprehensive financial review and strategic research report: Alligator Bioscience AB (ATORX) Analysis of corporate management and leadership competencies Alligator Bioscience's operational integrity and strategic development are fundamentally dictated by a management team that combines deep scientific background with specialized experience in biotechnological commercialization. The company, headquartered in Medicon Village in Lund, Sweden, has successfully evolved from a discovery-focused antibody shop to a clinical-stage powerhouse, a transition that requires a nuanced management approach to handle the high capital requirements associated with late-stage trials. The senior management is led by CEO Søren Bregenholt, who assumed the role in June 2021. Bregenholt brings a distinguished 20-year career in the global pharmaceutical and biotech sector with previous senior positions at Novo Nordisk, Symphogen, and Macrophage Pharma. His background is particularly relevant to Alligator's current needs, as he has a proven track record of negotiating and operationalizing licensing and co-development agreements, which are crucial for the company's "phase 3-ready" lead asset, mitazalimab. CFO Johan Giléus, appointed in 2024, complements the CEO. Giléus is an experienced finance director with over 25 years of experience leading financial operations and strategy across multiple sectors. His most recent role as CFO and Vice President at InDex Pharmaceuticals, where he oversaw a large clinical phase 3 trial and successfully managed a reverse merger, provides the specific financial engineering expertise Alligator needs to navigate its current capital structure challenges. The scientific vision is anchored by Peter Ellmark, Chief Scientific Officer, who has been an integral part of the company's management since 2018 and previously served as VP for Discovery. Ellmark's deep understanding of the proprietary RUBY™ and Neo-X-Prime™ platforms ensures that the company's research and development output remains scientifically stringent and differentiated in a crowded immuno-oncology market. The Board of Directors, with Hans-Peter Ostler as chairman, provides a robust layer of oversight with a diverse mix of scientific, industrial, and strategic expertise. Board members, such as Eva Sjökvist Saers and Karin Nordbladh, maintain a high degree of independence from major shareholders, which is a hallmark of strong corporate governance for a public entity. This independence is crucial for a micro-based biotech company, where strategic decisions, such as dilution rights or partnership terms, must balance the existing shareholder base with the company's long-term survival.
·15 t sittenThe opportunists strike again, a rise and they sell again and again. There's no one in the market anymore who has the guts to hold their shares for just a little longer term. What a sad development. What drives them are small gains. Hmm. I'd rather go for the big one and at the same time make a difference for human health :-)
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 Q4 -tulosraportti
63 päivää sitten
‧44 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·4 t sitten·3 t sitten · MuokattuThen this news is under That an abstract is under embargo means that the content is subject to a publication stop until a specific date and time. This is common in research, medicine, and journalism to ensure a coordinated release of news or results. Science & Public Science & Public +2 Here's what it means in practice: Confidentiality: The information in the abstract is confidential and may not be disseminated, published, or discussed publicly before the specified time. Purpose: Embargoes are often used at scientific conferences or journal publications so that journalists and researchers have time to prepare their reporting without anyone "jumping the gun". Academic works: For dissertations or theses, an embargo may mean that the entire text is locked (for example, due to patent applications or collaboration with companies), even if the title and author name are sometimes still visible. Duration: An embargo period usually lasts between 6 and 12 months, but at conferences, it is often only a matter of days or hours until the actual
- ·10 t sittenIt's only a matter of time before we go up over 1kr .. this text is copied Here you get the translation to Danish. I must say that they all possess good competencies :) Comprehensive financial investigation and strategic research report: Alligator Bioscience AB (ATORX) Analysis of company management and management competencies Alligator Bioscience's operational integrity and strategic development are fundamentally dictated by a management team that combines deep scientific background with specialized experience in biotechnological commercialization. The company, headquartered in Medicon Village in Lund, Sweden, has successfully evolved from a discovery-focused antibody shop to a clinical-stage powerhouse, a transition that requires a nuanced management strategy to handle the high capital requirements associated with late-stage studies. The senior management is led by CEO Søren Bregenholt, who assumed the role in June 2021. Bregenholt has a distinguished 20-year career in the global pharmaceutical and biotech sector with previous leading positions at Novo Nordisk, Symphogen, and Macrophage Pharma. His background is particularly relevant to Alligator's current needs, as he has a documented track record of negotiating and operationalizing license and co-development agreements, which is crucial for the company's "Phase 3-ready" leading asset, mitazalimab. CFO Johan Giléus, appointed in 2024, complements the CEO. Giléus is an experienced finance director with over 25 years of experience leading financial operations and strategy across multiple sectors. His most recent role as CFO and VP at InDex Pharmaceuticals, where he oversaw a large clinical Phase 3 study and successfully managed a reverse merger, provides the specific financial engineering expertise Alligator needs to navigate its current capital structure challenges. The scientific vision is anchored by Peter Ellmark, Chief Scientific Officer, who has been an integral part of the company's management since 2018 and previously served as VP for Discovery. Ellmark's deep understanding of the proprietary RUBY™ and Neo-X-Prime™ platforms ensures that the company's research and development results remain scientifically stringent and differentiated in an overcrowded immuno-oncology market. The Board of Directors, with Hans-Peter Ostler as chairman, provides a robust oversight layer with a varied mix of scientific, industrial, and strategic expertise. Board members, such as Eva Sjökvist Saers and Karin Nordbladh, maintain a high degree of independence from major shareholders, which is a hallmark of strong corporate governance for a public entity. This independence is crucial for a micro-based biotechnology company, where strategic decisions, such as dilution rights or partnership terms, must balance the existing shareholder base with the company's long-term survival.·6 t sittenand I who thought this stock would go to ten kroner in two days;-)
- 11 t sitten11 t sittenComprehensive Financial Investigation and Strategic Research Report: Alligator Bioscience AB (ATORX) https://g.co/gemini/share/c495a5c989b8·10 t sittenHere you get the translation into Danish. I must say that they all possess good competencies :) Comprehensive financial review and strategic research report: Alligator Bioscience AB (ATORX) Analysis of corporate management and leadership competencies Alligator Bioscience's operational integrity and strategic development are fundamentally dictated by a management team that combines deep scientific background with specialized experience in biotechnological commercialization. The company, headquartered in Medicon Village in Lund, Sweden, has successfully evolved from a discovery-focused antibody shop to a clinical-stage powerhouse, a transition that requires a nuanced management approach to handle the high capital requirements associated with late-stage trials. The senior management is led by CEO Søren Bregenholt, who assumed the role in June 2021. Bregenholt brings a distinguished 20-year career in the global pharmaceutical and biotech sector with previous senior positions at Novo Nordisk, Symphogen, and Macrophage Pharma. His background is particularly relevant to Alligator's current needs, as he has a proven track record of negotiating and operationalizing licensing and co-development agreements, which are crucial for the company's "phase 3-ready" lead asset, mitazalimab. CFO Johan Giléus, appointed in 2024, complements the CEO. Giléus is an experienced finance director with over 25 years of experience leading financial operations and strategy across multiple sectors. His most recent role as CFO and Vice President at InDex Pharmaceuticals, where he oversaw a large clinical phase 3 trial and successfully managed a reverse merger, provides the specific financial engineering expertise Alligator needs to navigate its current capital structure challenges. The scientific vision is anchored by Peter Ellmark, Chief Scientific Officer, who has been an integral part of the company's management since 2018 and previously served as VP for Discovery. Ellmark's deep understanding of the proprietary RUBY™ and Neo-X-Prime™ platforms ensures that the company's research and development output remains scientifically stringent and differentiated in a crowded immuno-oncology market. The Board of Directors, with Hans-Peter Ostler as chairman, provides a robust layer of oversight with a diverse mix of scientific, industrial, and strategic expertise. Board members, such as Eva Sjökvist Saers and Karin Nordbladh, maintain a high degree of independence from major shareholders, which is a hallmark of strong corporate governance for a public entity. This independence is crucial for a micro-based biotech company, where strategic decisions, such as dilution rights or partnership terms, must balance the existing shareholder base with the company's long-term survival.
- ·15 t sittenThe opportunists strike again, a rise and they sell again and again. There's no one in the market anymore who has the guts to hold their shares for just a little longer term. What a sad development. What drives them are small gains. Hmm. I'd rather go for the big one and at the same time make a difference for human health :-)
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Nasdaq Stockholm
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 22 892 | - | - | ||
| 14 553 | - | - | ||
| 22 703 | - | - | ||
| 19 262 | - | - | ||
| 18 484 | - | - |
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 5.5. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 12.2. | ||
2025 Q3 -tulosraportti 23.10.2025 | ||
2025 Q2 -tulosraportti 10.7.2025 | ||
2025 Q1 -tulosraportti 24.4.2025 | ||
2024 Q4 -tulosraportti 22.1.2025 |
2025 Q4 -tulosraportti
63 päivää sitten
‧44 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 5.5. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 12.2. | ||
2025 Q3 -tulosraportti 23.10.2025 | ||
2025 Q2 -tulosraportti 10.7.2025 | ||
2025 Q1 -tulosraportti 24.4.2025 | ||
2024 Q4 -tulosraportti 22.1.2025 |
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·4 t sitten·3 t sitten · MuokattuThen this news is under That an abstract is under embargo means that the content is subject to a publication stop until a specific date and time. This is common in research, medicine, and journalism to ensure a coordinated release of news or results. Science & Public Science & Public +2 Here's what it means in practice: Confidentiality: The information in the abstract is confidential and may not be disseminated, published, or discussed publicly before the specified time. Purpose: Embargoes are often used at scientific conferences or journal publications so that journalists and researchers have time to prepare their reporting without anyone "jumping the gun". Academic works: For dissertations or theses, an embargo may mean that the entire text is locked (for example, due to patent applications or collaboration with companies), even if the title and author name are sometimes still visible. Duration: An embargo period usually lasts between 6 and 12 months, but at conferences, it is often only a matter of days or hours until the actual
- ·10 t sittenIt's only a matter of time before we go up over 1kr .. this text is copied Here you get the translation to Danish. I must say that they all possess good competencies :) Comprehensive financial investigation and strategic research report: Alligator Bioscience AB (ATORX) Analysis of company management and management competencies Alligator Bioscience's operational integrity and strategic development are fundamentally dictated by a management team that combines deep scientific background with specialized experience in biotechnological commercialization. The company, headquartered in Medicon Village in Lund, Sweden, has successfully evolved from a discovery-focused antibody shop to a clinical-stage powerhouse, a transition that requires a nuanced management strategy to handle the high capital requirements associated with late-stage studies. The senior management is led by CEO Søren Bregenholt, who assumed the role in June 2021. Bregenholt has a distinguished 20-year career in the global pharmaceutical and biotech sector with previous leading positions at Novo Nordisk, Symphogen, and Macrophage Pharma. His background is particularly relevant to Alligator's current needs, as he has a documented track record of negotiating and operationalizing license and co-development agreements, which is crucial for the company's "Phase 3-ready" leading asset, mitazalimab. CFO Johan Giléus, appointed in 2024, complements the CEO. Giléus is an experienced finance director with over 25 years of experience leading financial operations and strategy across multiple sectors. His most recent role as CFO and VP at InDex Pharmaceuticals, where he oversaw a large clinical Phase 3 study and successfully managed a reverse merger, provides the specific financial engineering expertise Alligator needs to navigate its current capital structure challenges. The scientific vision is anchored by Peter Ellmark, Chief Scientific Officer, who has been an integral part of the company's management since 2018 and previously served as VP for Discovery. Ellmark's deep understanding of the proprietary RUBY™ and Neo-X-Prime™ platforms ensures that the company's research and development results remain scientifically stringent and differentiated in an overcrowded immuno-oncology market. The Board of Directors, with Hans-Peter Ostler as chairman, provides a robust oversight layer with a varied mix of scientific, industrial, and strategic expertise. Board members, such as Eva Sjökvist Saers and Karin Nordbladh, maintain a high degree of independence from major shareholders, which is a hallmark of strong corporate governance for a public entity. This independence is crucial for a micro-based biotechnology company, where strategic decisions, such as dilution rights or partnership terms, must balance the existing shareholder base with the company's long-term survival.·6 t sittenand I who thought this stock would go to ten kroner in two days;-)
- 11 t sitten11 t sittenComprehensive Financial Investigation and Strategic Research Report: Alligator Bioscience AB (ATORX) https://g.co/gemini/share/c495a5c989b8·10 t sittenHere you get the translation into Danish. I must say that they all possess good competencies :) Comprehensive financial review and strategic research report: Alligator Bioscience AB (ATORX) Analysis of corporate management and leadership competencies Alligator Bioscience's operational integrity and strategic development are fundamentally dictated by a management team that combines deep scientific background with specialized experience in biotechnological commercialization. The company, headquartered in Medicon Village in Lund, Sweden, has successfully evolved from a discovery-focused antibody shop to a clinical-stage powerhouse, a transition that requires a nuanced management approach to handle the high capital requirements associated with late-stage trials. The senior management is led by CEO Søren Bregenholt, who assumed the role in June 2021. Bregenholt brings a distinguished 20-year career in the global pharmaceutical and biotech sector with previous senior positions at Novo Nordisk, Symphogen, and Macrophage Pharma. His background is particularly relevant to Alligator's current needs, as he has a proven track record of negotiating and operationalizing licensing and co-development agreements, which are crucial for the company's "phase 3-ready" lead asset, mitazalimab. CFO Johan Giléus, appointed in 2024, complements the CEO. Giléus is an experienced finance director with over 25 years of experience leading financial operations and strategy across multiple sectors. His most recent role as CFO and Vice President at InDex Pharmaceuticals, where he oversaw a large clinical phase 3 trial and successfully managed a reverse merger, provides the specific financial engineering expertise Alligator needs to navigate its current capital structure challenges. The scientific vision is anchored by Peter Ellmark, Chief Scientific Officer, who has been an integral part of the company's management since 2018 and previously served as VP for Discovery. Ellmark's deep understanding of the proprietary RUBY™ and Neo-X-Prime™ platforms ensures that the company's research and development output remains scientifically stringent and differentiated in a crowded immuno-oncology market. The Board of Directors, with Hans-Peter Ostler as chairman, provides a robust layer of oversight with a diverse mix of scientific, industrial, and strategic expertise. Board members, such as Eva Sjökvist Saers and Karin Nordbladh, maintain a high degree of independence from major shareholders, which is a hallmark of strong corporate governance for a public entity. This independence is crucial for a micro-based biotech company, where strategic decisions, such as dilution rights or partnership terms, must balance the existing shareholder base with the company's long-term survival.
- ·15 t sittenThe opportunists strike again, a rise and they sell again and again. There's no one in the market anymore who has the guts to hold their shares for just a little longer term. What a sad development. What drives them are small gains. Hmm. I'd rather go for the big one and at the same time make a difference for human health :-)
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Nasdaq Stockholm
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 22 892 | - | - | ||
| 14 553 | - | - | ||
| 22 703 | - | - | ||
| 19 262 | - | - | ||
| 18 484 | - | - |
Välittäjätilasto
Dataa ei löytynyt